DOSE — Rapid Dose Therapeutics Share Price
Last trade - 00:00- CA$18.70m
- CA$20.93m
- CA$1.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 15.86 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -423.29% | ||
Financial Summary
| Year End 29th Feb | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.1 | 0.76 | 1.75 | 0.72 | 1.02 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. It provides disruptive drug delivery technologies designed to improve patient outcomes. Its flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. It has one operating segment comprising production, distribution, research, and the provision of technical services for the delivery of oral thin film strips containing active ingredients. It offers over-the-counter and pharmaceutical drug delivery solutions. Its QuickStrip Energy delivers energizing caffeine. Its QuickStrip B12 delivers vitamin B12 to the system, assisting with metabolism and physical energy. Its QuickStrip Sleep delivers melatonin to the system, inducing natural and healthy sleep. QuickStrip Lidocaine is its dental product.
Directors
- Last Annual
- February 29th, 2024
- Last Interim
- May 31st, 2024
- Incorporated
- February 27th, 2008
- Public Since
- December 17th, 2018
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 124,636,166
- Address
- 1121 Walkers Line, Unit 3A, BURLINGTON, L7N 2G4
- Web
- Phone
- +1 4164771052
- Auditors
- SRCO Professional Corporation
Latest News for DOSE
Upcoming Events for DOSE
Q2 2024 Rapid Dose Therapeutics Corp Earnings Release
Q3 2024 Rapid Dose Therapeutics Corp Earnings Release
Similar to DOSE
Aquarius Surgical Technologies
Canadian Securities Exchange
Cannabix Technologies
Canadian Securities Exchange
Cognetivity Neurosciences
Canadian Securities Exchange
Gemina Laboratories
Canadian Securities Exchange
Imagin Medical
Canadian Securities Exchange
FAQ
As of Today at 23:20 UTC, shares in Rapid Dose Therapeutics are trading at CA$0.15. This share price information is delayed by 15 minutes.
Shares in Rapid Dose Therapeutics last closed at CA$0.15 and the price had moved by +36.36% over the past 365 days. In terms of relative price strength the Rapid Dose Therapeutics share price has outperformed the Toronto Stock Exchange 300 Composite Index by +19.32% over the past year.
The overall consensus recommendation for Rapid Dose Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRapid Dose Therapeutics does not currently pay a dividend.
Rapid Dose Therapeutics does not currently pay a dividend.
Rapid Dose Therapeutics does not currently pay a dividend.
To buy shares in Rapid Dose Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.15, shares in Rapid Dose Therapeutics had a market capitalisation of CA$18.70m.
Here are the trading details for Rapid Dose Therapeutics:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: DOSE
Based on an overall assessment of its quality, value and momentum Rapid Dose Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rapid Dose Therapeutics is CA$1.80. That is 1100% above the last closing price of CA$0.15.
Analysts covering Rapid Dose Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rapid Dose Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -13.14%.
As of the last closing price of CA$0.15, shares in Rapid Dose Therapeutics were trading -14.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rapid Dose Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rapid Dose Therapeutics' management team is headed by:
- Mark Upsdell - PRE
- Doug Hyland - CFO
- Jason Lewis - SVP
- Peter Hasler - IND